
NovoCure Limited – NASDAQ:NVCR
NovoCure Limited stock price today
NovoCure Limited stock price monthly change
NovoCure Limited stock price quarterly change
NovoCure Limited stock price yearly change
NovoCure Limited key metrics
Market Cap | 3.24B |
Enterprise value | 7.34B |
P/E | -73.57 |
EV/Sales | 13.65 |
EV/EBITDA | -122.38 |
Price/Sales | 12.78 |
Price/Book | 15.58 |
PEG ratio | 1.28 |
EPS | -1.8 |
Revenue | 525.65M |
EBITDA | -158.63M |
Income | -192.74M |
Revenue Q/Q | 13.35% |
Revenue Y/Y | 0.60% |
Profit margin | -17.2% |
Oper. margin | -16.64% |
Gross margin | 78.64% |
EBIT margin | -16.64% |
EBITDA margin | -30.18% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNovoCure Limited stock price history
NovoCure Limited stock forecast
NovoCure Limited financial statements
$30
Potential upside: 148.77%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 126.05M | -57.41M | -45.55% |
---|---|---|---|
Sep 2023 | 127.32M | -49.48M | -38.87% |
Dec 2023 | 133.78M | -47.07M | -35.19% |
Mar 2024 | 138.50M | -38.76M | -27.98% |
2022-10-27 | -0.23947 | -0.25 |
---|---|---|
2022-12-31 | -0.34615 | -0.35518 |
2023-02-23 | -0.42491 | -0.36 |
Jun 2023 | 1159015000 | 743.33M | 64.13% |
---|---|---|---|
Sep 2023 | 1146353000 | 752.64M | 65.66% |
Dec 2023 | 1146129000 | 783.63M | 68.37% |
Mar 2024 | 1121429000 | 762.07M | 67.96% |
Jun 2023 | -22.73M | -13.89M | 7.50M |
---|---|---|---|
Sep 2023 | -19.31M | 17.25M | 1.17M |
Dec 2023 | -14.55M | 98.5M | 1.91M |
Mar 2024 | -31.57M | 246.21M | 213K |
NovoCure Limited alternative data
Aug 2023 | 1,320 |
---|---|
Sep 2023 | 1,320 |
Oct 2023 | 1,320 |
Nov 2023 | 1,320 |
Dec 2023 | 1,320 |
Jan 2024 | 1,320 |
Feb 2024 | 1,320 |
Mar 2024 | 1,453 |
Apr 2024 | 1,453 |
May 2024 | 1,453 |
Jun 2024 | 1,453 |
Jul 2024 | 1,453 |
NovoCure Limited other data
Period | Buy | Sel |
---|---|---|
Aug 2023 | 0 | 1144 |
Sep 2023 | 0 | 1450 |
Nov 2023 | 0 | 382 |
Feb 2024 | 0 | 4381 |
Mar 2024 | 0 | 5843 |
Jun 2024 | 0 | 2892 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | GROENHUYSEN WILHELMUS CM officer: Chief Op.. | Ordinary Shares | 124,373 | $22.82 | $2,838,192 | ||
Option | GROENHUYSEN WILHELMUS CM officer: Chief Op.. | Stock Options (Right to buy) | 124,373 | $7.15 | $889,267 | ||
Sale | VERNON W ANTHONY director | Ordinary Shares | 964 | $23.89 | $23,033 | ||
Sale | SCANNELL TIMOTHY J director | Ordinary Shares | 964 | $23.89 | $23,027 | ||
Sale | LEUNG GABRIEL director | Ordinary Shares | 964 | $23.89 | $23,025 | ||
Sale | GROENHUYSEN WILHELMUS CM officer: Chief Op.. | Ordinary Shares | 1,217 | $16.01 | $19,484 | ||
Sale | LEONARD FRANK X officer: EVP, Pres., Novocure O.. | Ordinary Shares | 840 | $16.01 | $13,448 | ||
Sale | GROENHUYSEN WILHELMUS CM officer: Chief Op.. | Ordinary Shares | 2,107 | $16.03 | $33,769 | ||
Sale | LEONARD FRANK X officer: EVP, Pres., Novocure O.. | Ordinary Shares | 1,679 | $16.03 | $26,909 | ||
Sale | LEONARD FRANK X officer: EVP, Pres., Novocure O.. | Ordinary Shares | 2,078 | $16.14 | $33,545 |
Patent |
---|
Grant Filling date: 8 Apr 2019 Issue date: 12 Apr 2022 |
Grant Filling date: 4 Sep 2018 Issue date: 2 Nov 2021 |
Grant Utility: Treating patients with TTFields with the electrode positions optimized using deformable templates Filling date: 13 Dec 2017 Issue date: 7 Sep 2021 |
Grant Filling date: 11 Aug 2017 Issue date: 24 Aug 2021 |
Grant Utility: TTField treatment with optimization of electrode positions on the head based on MRI-based conductivity measurements Filling date: 17 Dec 2018 Issue date: 25 May 2021 |
Grant Filling date: 3 Apr 2017 Issue date: 3 Nov 2020 |
Grant Utility: Optimizing treatment using TTfields by changing the frequency during the course of long term tumor treatment Filling date: 21 Apr 2017 Issue date: 22 Sep 2020 |
Application Filling date: 4 Sep 2018 Issue date: 5 Mar 2020 |
Grant Filling date: 29 Jun 2017 Issue date: 15 Oct 2019 |
Application TTField Treatment with Optimization of Electrode Positions Based on Low Frequency (<1MHZ) AC Conductivity Estimates Derived From Two MRI Images Having Different Repetition Times Filling date: 9 Apr 2019 Issue date: 10 Oct 2019 |
Quarter | Transcript |
---|---|
Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 26 Oct 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
NovoCure: Loading Up On Growth Catalysts
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
NovoCure: Significant Upside Even Without A Breakthrough
NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum
NovoCure At 5 Year Lows: Avoid Or Opportunity?
NovoCure: Pipeline Conversion Is Key
Exploring The Potential Of NovoCure's TTFields In Non-Small Cell Lung Cancer
NovoCure: Ramifications Of Recent Management Change
NovoCure: Catalysts Stacking For More Upside
-
What's the price of NovoCure Limited stock today?
One share of NovoCure Limited stock can currently be purchased for approximately $12.06.
-
When is NovoCure Limited's next earnings date?
Unfortunately, NovoCure Limited's (NVCR) next earnings date is currently unknown.
-
Does NovoCure Limited pay dividends?
No, NovoCure Limited does not pay dividends.
-
How much money does NovoCure Limited make?
NovoCure Limited has a market capitalization of 3.24B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 5.3% to 509.34M US dollars. NovoCure Limited made a loss 207.04M US dollars in net income (profit) last year or -$0.36 on an earnings per share basis.
-
What is NovoCure Limited's stock symbol?
NovoCure Limited is traded on the NASDAQ under the ticker symbol "NVCR".
-
What is NovoCure Limited's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of NovoCure Limited?
Shares of NovoCure Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are NovoCure Limited's key executives?
NovoCure Limited's management team includes the following people:
- Mr. Asaf Danziger Pres, Chief Executive Officer & Director(age: 59, pay: $2,010,000)
- Mr. William F. Doyle Executive Chairman(age: 63, pay: $1,830,000)
- Mr. Wilhelmus C. M. Groenhuysen Chief Operating Officer(age: 67, pay: $1,440,000)
- Mr. Todd C. Longsworth Gen. Counsel(age: 50, pay: $1,150,000)
- Ms. Ashley Cordova Chief Financial Officer & Vice President of Investor Relations(age: 46, pay: $995,200)
- Mr. Pritesh Shah Chief Commercial Officer(age: 47, pay: $946,170)
-
How many employees does NovoCure Limited have?
As Jul 2024, NovoCure Limited employs 1,453 workers.
-
When NovoCure Limited went public?
NovoCure Limited is publicly traded company for more then 9 years since IPO on 1 Oct 2015.
-
What is NovoCure Limited's official website?
The official website for NovoCure Limited is novocure.com.
-
How can i contact NovoCure Limited?
NovoCure Limited can be reached via phone at +44 1534 756700.
-
What is NovoCure Limited stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for NovoCure Limited in the last 12 months, the avarage price target is $30. The average price target represents a 148.77% change from the last price of $12.06.
NovoCure Limited company profile:

NovoCure Limited
novocure.comNASDAQ
1,453
Medical - Instruments & Supplies
Healthcare
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Saint Helier, JE2 4UF
CIK: 0001645113
ISIN: JE00BYSS4X48
CUSIP: G6674U108